RecruitingNausea and VomitingObesity
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Eligible age
18–65 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
Sponsor: Vanda Pharmaceuticals
You may qualify if…
- ✓ Body Mass Index ≥ 25 and \< 40 kg/m\^2
- ✓ No serious medical problems or chronic diseases, specifically no type I or type II diabetes
You may not qualify if…
- ✕ Another disorder that contributes to gastrointestinal symptoms
- ✕ History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
- ✕ History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
- ✕ Exposure to any investigational medication within the past 60 days
Where it's recruiting
California
Los Angeles · San Diego · San Jose
Florida
Tampa
New Jersey
Hamilton
New York
New York · Syosset
Texas
Plano · San Antonio
Virginia
Burke
Source: ClinicalTrials.gov · NCT07446439 · last updated 2026-04-20